Gapping up
In reaction to strong earnings/guidance:
- CPRX +8.3%, PAM +3.5%
Other news:
- CELG +1% (FDA has granted Breakthrough Therapy designation to POMALYST for the treatment of patients with HIV-positive Kaposi sarcoma)
Analyst comments:
- RMTI +11.8% (initiated with a Buy at H.C. Wainwright; tgt $11)
- WEN +0.7% (initiated with an Overweight at Piper Jaffray)